 Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Descriptor ID |
D006528
|
| MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
| Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Liver Cell Carcinoma, Adult
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma
- Carcinoma, Liver Cell
- Carcinomas, Liver Cell
- Cell Carcinoma, Liver
- Cell Carcinomas, Liver
- Liver Cell Carcinomas
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in this website by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 2 | 1 | 3 | | 2002 | 1 | 1 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 5 | 1 | 6 | | 2005 | 3 | 2 | 5 | | 2006 | 3 | 2 | 5 | | 2007 | 11 | 1 | 12 | | 2008 | 11 | 1 | 12 | | 2009 | 11 | 1 | 12 | | 2010 | 13 | 0 | 13 | | 2011 | 12 | 2 | 14 | | 2012 | 10 | 1 | 11 | | 2013 | 14 | 3 | 17 | | 2014 | 10 | 2 | 12 | | 2015 | 10 | 1 | 11 | | 2016 | 14 | 2 | 16 | | 2017 | 10 | 0 | 10 | | 2018 | 16 | 0 | 16 | | 2019 | 8 | 2 | 10 | | 2020 | 13 | 0 | 13 | | 2021 | 9 | 0 | 9 | | 2022 | 16 | 1 | 17 | | 2023 | 20 | 0 | 20 | | 2024 | 20 | 2 | 22 | | 2025 | 27 | 1 | 28 | | 2026 | 11 | 1 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles.
-
Benson AB, D'Angelica MI, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Burgoyne A, Castellanos J, Chokshi S, Cleary J, Cloyd J, Cullinan D, Dendy Case M, Franses J, Goyal L, Harris W, Jennings L, Kelley RK, Khan S, Krishnan M, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Wo J, Yano M, Yopp A, Zhao K, Schonfeld R, Stein M, Hochstetler C. NCCN Guidelines® Insights: Hepatocellular Carcinoma, Version 2.2026. J Natl Compr Canc Netw. 2026 Oct; 24(10).
-
Huang Y, Santoni G, Petrick JL, Wocalewski V, Sparrelid E, Xie SH. Menopausal hormone therapy and risk of liver cancer in a Swedish population-based cohort study. J Natl Cancer Inst. 2026 Aug 01; 118(8):1478-1484.
-
Vogel A, Ben Khaled N, Ramirez JR, Marhenke S, Siegler G, Siebler J, Lindig U, Schwartz G, Schultheiss M, Mueller T, Simon H, De Toni EN, Karl D, Al-Batran SE, Saborowski A. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. Eur J Cancer. 2026 Jul 26; 243:116847.
-
Yuza K, Kawashima J, Hobeika C, Lesurtel M, Aucejo F, Marques HP, Lam V, Hugh T, Popescu I, Gholami S, Weiss MJ, Martel G, Ratti F, Poultsides GA, Ruzzenente A, Endo I, Gleisner A, Bauer TW, Shen F, Maithel SK, Groot Koerkamp B, Pulitano C, Pawlik TM. Preoperative ALBI and APRI are independently associated with liver-related complications after curative-intent hepatectomy. HPB (Oxford). 2026 09; 28(9):1203-1213.
-
El Adel S, Jaradat D, Hoogteijling TJ, Koh YX, Cacciaguerra AB, Conci S, Aghayan D, Casellas M, Magistri P, Osei-Bordom D, Rusolillo N, de Meyere C, Zozaya G, Fisenko D, Ardito F, Lopez-Lopez V, Ahmad J, White S, Schmelzle M, Gallagher T, Sparrelid E, Sucandy I, Serrano PE, Geller D, Alseidi A, Croner RS, Dagher I, Primrose JN, Jovine E, Vrochides D, Memeo R, Daradka KIM, Besselink MG, Swijnenburg RJ, Robles-Campos R, Giuliante F, Efanov M, Rotellar F, D'Hondt M, Ferrero A, Sutcliffe RP, Di Benedetto F, López-Ben S, Edwin B, Ruzzenente A, Vivarelli M, Goh BKP, Hilal MA. Anatomical versus non-anatomical liver resection for hepatocellular carcinoma - an international multicenter propensity score-matched analysis of short- and long-term outcomes in an international multicenter cohort. HPB (Oxford). 2026 09; 28(9):1171-1181.
-
Huang Y, Santoni G, Sparrelid E, Xie SH. Metformin use and the risk of liver cancer in a Swedish population-based cohort study. JNCI Cancer Spectr. 2026 May 09; 10(3).
-
Baldo A, Akabane M, Kawashima J, Endo Y, Chatzipanagiotou OP, Sahara K, Ruzzenente A, Lesurtel M, Bauer TW, Marques HP, Martel G, Popescu I, Weiss MJ, Kitago M, Poultsides G, Sasaki K, Maithel SK, Hugh T, Gleisner A, Aucejo F, Pulitano C, Shen F, Koerkamp BG, Endo I, Spolverato G, Pawlik TM. Risk-adjusted cumulative sum (RA-CUSUM) method for real time monitoring of surgical units performance. HPB (Oxford). 2026 Jul; 28(7):987-995.
-
El Homsi M, Sabottke C, Singh C, Harmath C, Spieler B. Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis. Abdom Radiol (NY). 2026 Nov; 51(11):5337-5345.
-
Endo Y, Kawashima J, Chatzipanagiotou O, Woldesenbet S, Aucejo F, Marques HP, Lam V, Lesurtel M, Popescu I, Weiss M, Martel G, Poultsides GA, Ruzzenente A, Endo I, Gleisner A, Shen F, Pawlik TM. Machine learning-based clustering differentiates bilateral hepatocellular carcinoma characteristics and prognosis. Surgery. 2026 Jun; 194:110186.
-
Gu W, Ren Z, Gao J, Shen Z, Wang Y, Xu L, Qian R, Miao Q, Wu Y, Hu X, Wu Y, Liu W, Wan CC, Sun L, Cai Y, Sang M, Zheng C, Yan T. Inhibiting NAT10 suppresses hepatocellular carcinoma progression by reducing Nrf2 mRNA stability and increasing oxidative stress. Chem Biol Interact. 2026 Apr 25; 429:111972.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|